Allergan PLC (AGN)

252.95
2.61 1.02
NYSE : Health Care
Prev Close 255.56
Open 255.67
Day Low/High 251.94 / 255.70
52 Wk Low/High 195.50 / 339.00
Volume 2.28M
Avg Volume 3.62M
Exchange NYSE
Shares Outstanding 395.56M
Market Cap 102.94B
EPS 10.00
P/E Ratio 20.94
Div & Yield N.A. (N.A)

Latest News

Allergan Cures Its Ailing Chart

Allergan Cures Its Ailing Chart

The stock has broken free of tiresome resistance in a big way.

Chart of the Day: Allergan

The stock has broken free of tiresome resistance in a big way.

Allergan Generics Sale Clears FTC Hurdle

Blessing for the sale to Teva lifts regulatory overhang and empowers Allergan to deploy strategic capital initiatives.

3 Stocks Improving Performance Of The Health Care Sector

3 Stocks Improving Performance Of The Health Care Sector

TheStreet highlights 3 stocks pushing the health care sector higher today.

Allergan Receives Positive Opinion For Truberzi® (Eluxadoline) For Treatment Of Irritable Bowel Syndrome With Diarrhoea (IBS-D) In Adults

Allergan Receives Positive Opinion For Truberzi® (Eluxadoline) For Treatment Of Irritable Bowel Syndrome With Diarrhoea (IBS-D) In Adults

-- TRUBERZI® first-in-class medication offering sustained relief from multiple symptoms of IBS-D, such as pain, diarrhoea, urgency and bloating(1,2) --

Jim Cramer -- I Agree With the Analysts on Gap, Allergan

Jim Cramer -- I Agree With the Analysts on Gap, Allergan

Cramer agrees with analysts' bullish calls on Gap and Allergan.

Analysts' Actions -- Allergan, Alaska Air, Tableau, PulteGroup and More

Analysts' Actions -- Allergan, Alaska Air, Tableau, PulteGroup and More

Here are Monday's top research calls, including upgrades for Alaska Air and PulteGroup, a downgrade for Tableau Data and new coverage on Allergan.

Weekly Roundup

Stocks have an up-and-down week as the earnings floodgates open. Portfolio moves include cutting one position.

Biogen Should Either a Buyer or a Seller Be

Biogen Should Either a Buyer or a Seller Be

The company sans CEO Scangos needs to do some type of deal in the coming months.

Synergy Pharma Offers Lots of Synergies

Synergy Pharma Offers Lots of Synergies

I expect Allergan or another player to bid for SGYP soon.

Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal

Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal

Investors may want to look at some small-cap pharma names that could be takeover targets like Relypsa.

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.

Actress Marisa Tomei Partners With Allergan To Raise Awareness Of Chronic Dry Eye

Actress Marisa Tomei Partners With Allergan To Raise Awareness Of Chronic Dry Eye

- Famed actress launches charitable partnership with Guide Dogs for the Blind and discusses her experience and treatment with RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% -

Allergan And Adamas Announce New Expanded Indication For NAMZARIC® (Memantine And Donepezil Hydrochlorides) Extended Release For The Treatment Of Moderate To Severe Alzheimer's Disease

Allergan And Adamas Announce New Expanded Indication For NAMZARIC® (Memantine And Donepezil Hydrochlorides) Extended Release For The Treatment Of Moderate To Severe Alzheimer's Disease

-- Patients currently treated with donepezil hydrochloride 10 mg can now start therapy directly with once daily NAMZARIC --

'Mad Money' Lightning Round: Take Allergan Over Teva

'Mad Money' Lightning Round: Take Allergan Over Teva

Cramer is a fan of Danaher and says to stick with CBRL Group.

Jim Cramer's 'Mad Money' Recap: Was This a Bad Market Day? I'll Take It!

Jim Cramer's 'Mad Money' Recap: Was This a Bad Market Day? I'll Take It!

Monday's headlines predicted a gloomy earnings season, Cramer says. What were they thinking?

Cramer: These Stocks Are the Key to the Bull Market

Cramer: These Stocks Are the Key to the Bull Market

Let me give you the unassailable themes.

Weekly Roundup

Stocks kept climbing this week as earnings season got into high gear. We cut one name from the portfolio and rerated a few holdings.

Teva Makes Good Use of Rate Climate to Fund Allergan deal

Teva Makes Good Use of Rate Climate to Fund Allergan deal

The Israeli pharmaceutical company ought to achieve good terms as fixed-income investors flock to corporate bonds.

Allergan Deal Should Give Teva Va-Va-Voom

Allergan Deal Should Give Teva Va-Va-Voom

The drug maker is a compelling buy and has 50% upside potential over the next 18 to 24 months.

Shire Could Divest ADHD Treatment, Other Assets, for More Upside Post-Baxalta

Shire Could Divest ADHD Treatment, Other Assets, for More Upside Post-Baxalta

At least one company follower believes the divestiture of Shire's Neurology division for as much as $13 billion would be a logical next move.

The GOP's Tax Plan Is Great for Corporate America

The GOP's Tax Plan Is Great for Corporate America

The House Republicans' tax reform plan is a pretty good deal according to one analysis, especially for American corporations.

Trade Idea: Allergan

Continue a repair trade in AGN with a ratio call spread on top of stock already owned.

6 Big Stocks to Add to Your Buy List -- Plus 1 to Avoid

6 Big Stocks to Add to Your Buy List -- Plus 1 to Avoid

Here's a technical look at how to trade some of the most active stocks on the market right now.

Portfolio Positions We are Watching in Today's Trading

A look at how we are evaluating today’s market action.

Valeant, Chipotle Both Rise After Sequoia Trades One Troubled Stock For Another

Valeant, Chipotle Both Rise After Sequoia Trades One Troubled Stock For Another

Sequoia Fund has sold its position in Valeant Pharmaceuticals and has added four new positions.

Sequoia Fund Drops Valeant, Allergan and Cabela's

Sequoia Fund Drops Valeant, Allergan and Cabela's

The company once held a 30% stake in Valeant, now owns no Valeant shares.